High grade serous ovarian cancer (HGSOvCa) is a malignant tumor subtype that originates from the female reproductive system. The standard therapies prescribed to HGSOvCa patients include several chemotherapy cycles based on platinum-taxol drugs and a debulking surgery for removing the cancer tissues. A fundamental characteristic of this disease, that drastically decreases the 5-years survival rates, is the acquisition of chemotherapy resistance by the tumoral cells after the first-line treatment. Both the cancer aggressiveness and the development of the platinum resistance increase the necessity of a more effective and targeted therapy.During the last 10 years, a branch of the cancer research has focused its attention on the genomic components called "long non-coding RNAs".